The enzyme PARP1 helps repair single-stranded DNA breaks, and its inhibition shows antitumor efficacy in ovarian, breast, prostate and pancreatic cancers involving mutations in BRCA1 or BRCA2. However ...

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between September 17 th and 21 st was host to the session Mini oral session: GU tumours, ...

A new drug combo is more effective in treating advanced prostate cancer The targeted drug niraparib added to hormone therapy slowed cancer growth and symptom progression Signs show the combo might ...

Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients who still show symptoms after antihistamine treatment. The FDA has ...

Olaparib dominates with 86.2% market share in 2025. As the first FDA-approved PARP inhibitor, its clinical efficacy in ovarian and breast cancers, broad regulatory approvals, and favorable safety ...

The animation industry has always been labor-intensive, blending artistry, innovation, and technology to bring stories to life. Now, a new technological shift, generative AI (genAI), is sparking ...

This has to be looked at as a multifactorial issue, says Joseph Renzulli, MD, of Yale School of Medicine, who shares his perspectives on why that's the case. (3:22) Pelvic Lymph Node Dissection: Is It ...